Tyrosine kinase inhibitorFDA-approvedSecond-line
Alecensa
Generic name: alectinib
How it works
Blocks the activity of the anaplastic lymphoma kinase (ALK) protein, which is involved in the growth and spread of cancer cells.
Cancer types
Lung Cancer— ALK-positive
Efficacy
In clinical trials, alectinib improved progression-free survival in patients with ALK-positive non-small cell lung cancer, with a median survival of approximately 25.7 months.
Side effects
Moderate
Side effects can be significant and may require dose adjustments or supportive medication, but the treatment is usually continued.
Evidence from research
| Study | Cancer type | Stage | Efficacy | |
|---|---|---|---|---|
| Comparing Two Cancer Treatments in Lung Cancer Patients | Lung Cancer | observational | The 3-year progression-free survival rate was 51.5% for brigatinib and 62.1% for alectinib. | Source → |
| Researchers Report a Rare Case of Cancer Remission in Stage IV Lung Cancer Patient | Lung Cancer | observational | — | Source → |
| Combining Cancer Treatments Increases Risk of Lung Damage | Lung Cancer | observational | — | Source → |
This information is provided for general education only and is not medical advice. Always consult a qualified healthcare professional before making treatment decisions.